PUBLISHER: 360iResearch | PRODUCT CODE: 1600101
PUBLISHER: 360iResearch | PRODUCT CODE: 1600101
Hepatorenal Syndrome Treatment Market by Type (Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome), Treatment (Surgical Treatment, Therapeutics), End-User - Global Forecast 2025-2030
The Hepatorenal Syndrome Treatment Market was valued at USD 4.56 billion in 2023, expected to reach USD 4.80 billion in 2024, and is projected to grow at a CAGR of 5.47%, to USD 6.62 billion by 2030.
Hepatorenal syndrome (HRS) treatment is focused on managing a complex condition characterized by rapid kidney deterioration in individuals with advanced liver disease. The scope includes pharmaceutical therapies such as vasoconstrictors and albumin, dialysis modalities, liver transplants, and emerging biologics. The necessity of HRS treatment arises due to the condition's association with high morbidity and mortality rates, making early and effective intervention critical in improving patient outcomes. Its application spans across hospital settings, clinics, and research institutions, primarily targeting patients with conditions like cirrhosis and those awaiting liver transplants. Insights into the HRS treatment market highlight substantial growth propelled by an increase in liver diseases globally, advancements in therapeutic methods, and a growing transplant recipient population. However, the market faces limitations, such as the high cost of treatment, limited availability of transplant organs, and regulatory challenges that hinder approval processes for new therapies. In terms of opportunity, the market holds potential in the development of novel biomarkers and therapies that offer targeted treatment solutions. Collaborations between pharmaceutical companies and research organizations can accelerate drug discovery and enhance therapeutic strategies. Investment in R&D and adaptive clinical trial designs could also lead to the development of personalized treatment plans, improving patient-specific outcomes. Market players are recommended to focus on innovation in biologics and regenerative medicines, which present promising avenues given the unmet clinical needs. Challenges lay in navigating the stringent regulatory landscapes and addressing the affordability of treatments, which require strategic pricing and enhanced healthcare policies to facilitate widespread accessibility. Recognizing the multidimensional nature of the market, businesses should also explore partnerships with digital health companies to develop platforms that allow for better disease management and patient adherence to therapy regimens, leveraging data for improved health outcomes.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 4.56 billion |
| Estimated Year [2024] | USD 4.80 billion |
| Forecast Year [2030] | USD 6.62 billion |
| CAGR (%) | 5.47% |
Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hepatorenal Syndrome Treatment Market
The Hepatorenal Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.
- Market Drivers
- Rising prevalence of hepatorenal syndrome
- Increasing fast track and orphan drug designations
- Growing disease awareness & patient support programs
- Market Restraints
- High treatment costs, and product recall incidents
- Market Opportunities
- Increasing research & development to incorporate advanced technologies
- Increased funding and venture capital for biotech start-ups focusing on innovative HRS treatments
- Market Challenges
- Side-effects and risks related to drug usage
Porter's Five Forces: A Strategic Tool for Navigating the Hepatorenal Syndrome Treatment Market
Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hepatorenal Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.
PESTLE Analysis: Navigating External Influences in the Hepatorenal Syndrome Treatment Market
External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hepatorenal Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.
Market Share Analysis: Understanding the Competitive Landscape in the Hepatorenal Syndrome Treatment Market
A detailed market share analysis in the Hepatorenal Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.
FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hepatorenal Syndrome Treatment Market
The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hepatorenal Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.
Strategy Analysis & Recommendation: Charting a Path to Success in the Hepatorenal Syndrome Treatment Market
A strategic analysis of the Hepatorenal Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.
Key Company Profiles
The report delves into recent significant developments in the Hepatorenal Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Aetna Inc., Baxter International Inc, Becton, Dickinson and Company, Biocon Limited, BioVie Inc, Cadila Healthcare Limited, Cumberland Pharmaceuticals Inc, Edwards Lifesciences Corporation, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Mallinckrodt Inc, Medtronic plc, Neovii Pharmaceuticals AG, Novartis International AG, Orphan Therapeutics, LLC, PharmaIN Corporation, Samarth Life Sciences Pvt Ltd., Swastik Life Sciences, and United Biotech Pvt Ltd..
Market Segmentation & Coverage
This research report categorizes the Hepatorenal Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Based on Type, market is studied across Type 1 Hepatorenal Syndrome and Type 2 Hepatorenal Syndrome.
- Based on Treatment, market is studied across Surgical Treatment and Therapeutics. The Surgical Treatment is further studied across Liver Transplantation, Renal Replacement Therapy, and Surgical Shunting. The Therapeutics is further studied across Glypressin, Lucassin, and Terlivaz.
- Based on End-User, market is studied across Academic & Research Institutes, Ambulatory Surgical Centers, and Hospitals & Clinics.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
The report offers a comprehensive analysis of the market, covering key focus areas:
1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.
2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.
3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.
4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.
5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.
The report also answers critical questions to aid stakeholders in making informed decisions:
1. What is the current market size, and what is the forecasted growth?
2. Which products, segments, and regions offer the best investment opportunities?
3. What are the key technology trends and regulatory influences shaping the market?
4. How do leading vendors rank in terms of market share and competitive positioning?
5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising prevalence of hepatorenal syndrome
- 5.1.1.2. Increasing fast track and orphan drug designations
- 5.1.1.3. Growing disease awareness & patient support programs
- 5.1.2. Restraints
- 5.1.2.1. High treatment costs, and product recall incidents
- 5.1.3. Opportunities
- 5.1.3.1. Increasing research & development to incorporate advanced technologies
- 5.1.3.2. Increased funding and venture capital for biotech start-ups focusing on innovative HRS treatments
- 5.1.4. Challenges
- 5.1.4.1. Side-effects and risks related to drug usage
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.2.1. Treatment: Ongoing innovations to improve the efficacy and treatment outcomes of surgical interventions
- 5.2.2. End-User: Availability of comprehensive healthcare solutions and services in hospitals and clinics
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
- 5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
6. Hepatorenal Syndrome Treatment Market, by Type
- 6.1. Introduction
- 6.2. Type 1 Hepatorenal Syndrome
- 6.3. Type 2 Hepatorenal Syndrome
7. Hepatorenal Syndrome Treatment Market, by Treatment
- 7.1. Introduction
- 7.2. Surgical Treatment
- 7.2.1. Liver Transplantation
- 7.2.2. Renal Replacement Therapy
- 7.2.3. Surgical Shunting
- 7.3. Therapeutics
- 7.3.1. Glypressin
- 7.3.2. Lucassin
- 7.3.3. Terlivaz
8. Hepatorenal Syndrome Treatment Market, by End-User
- 8.1. Introduction
- 8.2. Academic & Research Institutes
- 8.3. Ambulatory Surgical Centers
- 8.4. Hospitals & Clinics
9. Americas Hepatorenal Syndrome Treatment Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
10. Asia-Pacific Hepatorenal Syndrome Treatment Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
11. Europe, Middle East & Africa Hepatorenal Syndrome Treatment Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
12. Competitive Landscape
- 12.1. Market Share Analysis, 2023
- 12.2. FPNV Positioning Matrix, 2023
- 12.3. Competitive Scenario Analysis
- 12.3.1. Mallinckrodt Announces Key Study Results on TERLIVAZ for Hepatorenal Syndrome Reversal at SCCM 2023 Congress
- 12.3.2. FDA Approves First-Ever Treatment for Rapid Kidney Failures in Hepatorenal Syndrome
- 12.4. Strategy Analysis & Recommendation
Companies Mentioned
- 1. Aetna Inc.
- 2. Baxter International Inc
- 3. Becton, Dickinson and Company
- 4. Biocon Limited
- 5. BioVie Inc
- 6. Cadila Healthcare Limited
- 7. Cumberland Pharmaceuticals Inc
- 8. Edwards Lifesciences Corporation
- 9. F. Hoffmann-La Roche AG
- 10. GlaxoSmithKline plc
- 11. Mallinckrodt Inc
- 12. Medtronic plc
- 13. Neovii Pharmaceuticals AG
- 14. Novartis International AG
- 15. Orphan Therapeutics, LLC
- 16. PharmaIN Corporation
- 17. Samarth Life Sciences Pvt Ltd.
- 18. Swastik Life Sciences
- 19. United Biotech Pvt Ltd.
LIST OF FIGURES
- FIGURE 1. HEPATORENAL SYNDROME TREATMENT MARKET RESEARCH PROCESS
- FIGURE 2. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
- FIGURE 3. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 5. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 7. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 8. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
- FIGURE 9. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 10. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 11. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 12. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 13. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 14. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 15. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 16. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 17. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 20. HEPATORENAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
- FIGURE 21. HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
- TABLE 1. HEPATORENAL SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 6. HEPATORENAL SYNDROME TREATMENT MARKET DYNAMICS
- TABLE 7. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 8. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 1 HEPATORENAL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 2 HEPATORENAL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 11. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
- TABLE 13. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 14. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL SHUNTING, BY REGION, 2018-2030 (USD MILLION)
- TABLE 15. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 16. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GLYPRESSIN, BY REGION, 2018-2030 (USD MILLION)
- TABLE 18. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY LUCASSIN, BY REGION, 2018-2030 (USD MILLION)
- TABLE 19. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TERLIVAZ, BY REGION, 2018-2030 (USD MILLION)
- TABLE 20. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 21. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 22. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 23. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 24. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 25. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 26. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 27. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 28. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 29. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 30. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 31. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 32. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 33. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 34. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 35. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 36. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 37. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 38. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 39. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 40. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 41. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 42. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 43. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 44. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 45. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 46. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 47. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 48. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 49. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 50. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 51. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 52. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 53. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 54. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 55. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 56. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 57. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 58. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 59. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 60. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 61. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 62. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 63. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 64. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 65. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 66. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 67. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 68. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 69. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 70. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 71. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 72. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 73. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 74. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 75. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 76. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 77. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 78. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 79. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 80. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 81. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 82. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 83. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 84. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 85. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 86. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 87. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 88. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 89. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 90. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 91. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 92. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 93. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 94. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 95. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 96. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 97. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 98. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 99. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 100. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 101. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 102. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 103. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 104. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 105. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 106. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 107. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 108. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 109. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 110. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 111. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 112. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 113. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 114. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 115. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 116. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 117. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 118. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 119. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 120. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 121. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 122. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 123. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 124. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 125. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 126. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 127. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 128. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 129. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 130. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 131. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 132. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 133. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 134. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 135. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 136. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 137. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 138. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 139. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 140. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 141. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 142. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 143. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 144. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 145. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 146. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 147. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 148. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 149. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 150. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 151. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 152. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 153. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 154. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 155. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 156. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 157. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 158. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 159. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 160. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 161. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 162. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 163. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 164. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 165. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 166. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 167. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 168. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 169. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 170. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 171. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 172. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 173. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 174. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 175. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 176. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 177. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 178. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 179. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 180. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 181. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 182. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 183. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 184. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 185. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 186. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 187. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 188. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 189. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 190. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 191. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 192. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 193. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 194. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 195. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 196. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 197. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 198. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 199. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 200. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 201. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 202. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 203. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 204. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 205. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 206. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 207. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 208. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 209. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 210. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 211. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 212. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 213. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 214. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 215. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 216. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 217. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 218. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 219. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 220. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 221. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 222. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 223. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 224. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 225. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 226. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 227. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 228. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 229. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 230. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 231. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
- TABLE 232. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
- TABLE 233. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 234. HEPATORENAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 235. HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
